DNA-launched live-attenuated vaccines for biodefense applications

References

• Ferraro B, Morrow MP, Hutnick NA, et al. Clinical applications of DNA vaccines: current progress. Clin Infect Dis. 2011 Aug 1;53(3):296–302.
   PubMed Web of Science ®Google Scholar
• Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet. 2008 Oct;9(10):776–788.
   PubMed Web of Science ®Google Scholar
• Liu MA. DNA vaccines: an historical perspective and view to the future. Immunol Rev. 2011 Jan;239(1):62–84.
   PubMed Web of Science ®Google Scholar
• Sällberg M, Frelin L, Ahlén G, et al. Electroporation for therapeutic DNA vaccination in patients. Med Microbiol Immunol. 2015 Feb;204(1):131–135.
   PubMed Web of Science ®Google Scholar
• Dupuy LC, Schmaljohn CS. DNA vaccines for biodefense. Expert Rev Vaccines. 2009 Dec;8(12):1739–1754.
   PubMed Web of Science ®Google Scholar
• Schiller JT, Lowy DR. Raising expectations for subunit vaccine. J Infect Dis. 2015 May 1;211(9):1373–1375.
   PubMed Web of Science ®Google Scholar
• Pushko P, Pujanauski LM, Sun X, et al. Recombinant H7 hemagglutinin forms subviral particles that protect mice and ferrets from challenge with H7N9 influenza virus. Vaccine. 2015 Jul 21;33:4975–4982.
   PubMed Web of Science ®Google Scholar
• Pushko P, Pumpens P, Grens E. Development of virus-like particle technology from small highly symmetric to large complex virus-like particle structures. Intervirology. 2013;56(3):141–165.
   PubMed Web of Science ®Google Scholar
• Holtz KM, Robinson PS, Matthews EE, et al. Modifications of cysteine residues in the transmembrane and cytoplasmic domains of a recombinant hemagglutinin protein prevent cross-linked multimer formation and potency loss. BMC Biotechnol. 2014 Dec 24;14(1):1.
   PubMed Web of Science ®Google Scholar
• Ramshaw IA, Ramsay AJ. The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today. 2000 Apr;21(4):163–165.
   PubMedGoogle Scholar
• Villarreal DO, Talbott KT, Choo DK, et al. Synthetic DNA vaccine strategies against persistent viral infections. Expert Rev Vaccines. 2013 May;12(5):537–554.
   PubMed Web of Science ®Google Scholar
• Broderick KE, Humeau LM. Electroporation-enhanced delivery of nucleic acid vaccines. Expert Rev Vaccines. 2015 Feb;14(2):195–204.
   PubMed Web of Science ®Google Scholar
• Lambricht L, Lopes A, Kos S, et al. Clinical potential of electroporation for gene therapy and DNA vaccine delivery. Expert Opin Drug Deliv. 2016 Feb;13(2):295–310.
   PubMed Web of Science ®Google Scholar
• Dupuy LC, Richards MJ, Ellefsen B, et al. A DNA vaccine for venezuelan equine encephalitis virus delivered by intramuscular electroporation elicits high levels of neutralizing antibodies in multiple animal models and provides protective immunity to mice and nonhuman primates. Clin Vaccine Immunol. 2011 May;18(5):707–716.
   PubMed Web of Science ®Google Scholar
• Luke JM, Simon GG, Söderholm J, et al. Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine. J Virol. 2011 Feb;85(3):1370–1383.
   PubMed Web of Science ®Google Scholar
• Williams JA. Improving DNA vaccine performance through vector design. Curr Gene Ther. 2014;14(3):170–189.
   PubMed Web of Science ®Google Scholar
• Mairhofer J, Lara AR. Advances in host and vector development for the production of plasmid DNA vaccines. Methods Mol Biol. 2014;1139:505–541.
   PubMedGoogle Scholar
• Xenopoulos A, Pattnaik P. Production and purification of plasmid DNA vaccines: is there scope for further innovation? Expert Rev Vaccines. 2014 Dec;13(12):1537–1551.
   PubMed Web of Science ®Google Scholar
• Tretyakova I, Hearn J, Wang E, et al. DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice. J Infect Dis. 2014 Jun 15;209(12):1882–1890.
   PubMed Web of Science ®Google Scholar
• Tretyakova I, Lukashevich IS, Glass P, et al. Novel vaccine against Venezuelan equine encephalitis combines advantages of DNA immunization and a live attenuated vaccine. Vaccine. 2013 Feb 4;31(7):1019–1025.
   PubMed Web of Science ®Google Scholar
• Tretyakova I, Nickols B, Hidajat R, et al. Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in mice. Virology. 2014 Nov;468-470:28–35.
   PubMed Web of Science ®Google Scholar
• Hall RA, Nisbet DJ, Pham KB, et al. DNA vaccine coding for the full-length infectious Kunjin virus RNA protects mice against the New York strain of West Nile virus. Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10460–10464.
   PubMed Web of Science ®Google Scholar
• Mishin VP, Cominelli F, Yamshchikov VF. A ‘minimal’ approach in design of flavivirus infectious DNA. Virus Res. 2001 Dec 4;81(1–2):113–123.
   PubMed Web of Science ®Google Scholar
• Yamshchikov V. Development of a human live attenuated West Nile infectious DNA vaccine: conceptual design of the vaccine candidate. Virology. 2015 Oct;484:59–68.
   PubMed Web of Science ®Google Scholar
• Pushko P, Bredenbeek PB, Lukashevich IS. Experimental DNA-launched live-attenuated vaccines against infections caused by Flavi-and alphaviruses. In: Igor S, Lukashevich HS, editor. Novel technologies for vaccine development. Vienna: Springer Vienna; 2014.
   Google Scholar
• Minor PD. Live attenuated vaccines: historical successes and current challenges. Virology. 2015 May;479-480:379–392.
   PubMed Web of Science ®Google Scholar
• Coffey LL, Beeharry Y, Bordería AV, et al. Arbovirus high fidelity variant loses fitness in mosquitoes and mice. Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):16038–16043.
   PubMed Web of Science ®Google Scholar
• Weaver SC, Bellew LA, Gousset L, et al. Diversity within natural populations of eastern equine encephalomyelitis virus. Virology. 1993 Aug;195(2):700–709.
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Vaccines: past, present and future. Nat Med. 2005 Apr;11(4 Suppl):S5–11.
   PubMed Web of Science ®Google Scholar
• WHO. Standard operating procedure. Mutant analysis by PCR and restriction enzyme cleavage (MAPREC) for oral poliovirus (Sabin) vaccine types 1, 2 or 3. 2012 [cited 2015 May 27]. Available from: http://www.who.int/biologicals/vaccines/MAPREC_SOP_Final_09112012.pdf.
   Google Scholar
• Jiang X, Dalebout TJ, Lukashevich IS, et al. Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone. J Gen Virol. 2015 Apr;96(Pt 4):804–814.
   PubMed Web of Science ®Google Scholar
• Hidajat R, Nickols B, Forrester N, et al. Next generation sequencing of DNA-launched chikungunya vaccine virus. Virology. 2016 Mar;490:83–90.
   PubMed Web of Science ®Google Scholar
• Kilchert C, Wittmann S, Vasiljeva L. The regulation and functions of the nuclear RNA exosome complex. Nat Rev Mol Cell Biol. 2016 Jan 4;17:227–239.
   PubMed Web of Science ®Google Scholar
• Mansur DS, Smith GL, Ferguson BJ. Intracellular sensing of viral DNA by the innate immune system. Microbes Infect. 2014 Dec;16(12):1002–1012.
   PubMed Web of Science ®Google Scholar
• Barrett AD, Beasley DW. Development pathway for biodefense vaccines. Vaccine. 2009 Nov 5;27(Suppl 4):D2–7.
   PubMed Web of Science ®Google Scholar
• Weaver SC, Barrett AD. Transmission cycles, host range, evolution and emergence of arboviral disease. Nat Rev Microbiol. 2004 Oct;2(10):789–801.
   PubMed Web of Science ®Google Scholar
• Walsh SR, Dolin R. Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors. Expert Rev Vaccines. 2011 Aug;10(8):1221–1240.
   PubMed Web of Science ®Google Scholar
• Ljungberg K, Whitmore AC, Fluet ME, et al. Increased immunogenicity of a DNA-launched Venezuelan equine encephalitis virus-based replicon DNA vaccine. J Virol. 2007 Dec;81(24):13412–13423.
   PubMed Web of Science ®Google Scholar
• Bhat N, Fitzgerald KA. Recognition of cytosolic DNA by cGAS and other STING-dependent sensors. Eur J Immunol. 2014 Mar;44(3):634–640.
   PubMed Web of Science ®Google Scholar
• Coban C, Kobiyama K, Jounai N, et al. DNA vaccines: a simple DNA sensing matter? Hum Vaccin Immunother. 2013 Oct;9(10):2216–2221.
   PubMed Web of Science ®Google Scholar
• Wicker S, Seale H, Von Gierke L, et al. Vaccination of healthcare personnel: spotlight on groups with underlying conditions. Vaccine. 2014 Jul;32(32):4025–4031.
   PubMed Web of Science ®Google Scholar
• Haber P, Moro PL, Cano M, et al. Post-licensure surveillance of quadrivalent live attenuated influenza vaccine United States, Vaccine Adverse Event Reporting System (VAERS), July 2013-June 2014. Vaccine. 2015 Apr 15;33(16):1987–1992.
   PubMed Web of Science ®Google Scholar
• Turner PJ, Southern J, Andrews NJ, et al. Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study. Bmj. 2015;351:h6291.
   PubMed Web of Science ®Google Scholar
• Franceschini F, Bottau P, Caimmi S, et al. Vaccination in children with allergy to non active vaccine components. Clin Transl Med. 2015;4:3.
   PubMedGoogle Scholar
• Yamshchikov. Inventor infectious DNA as a vaccine against West Nile and other flaviviruses USA. US Patent 7459163 B2. 2008.
   Google Scholar
• Yamshchikov V, Manuvakhova M, Rodriguez E. Development of a human live attenuated West Nile infectious DNA vaccine: suitability of attenuating mutations found in SA14-14-2 for WN vaccine design. Virology. 2016 Nov 3;487:198–206.
   PubMed Web of Science ®Google Scholar
• Yamshchikov V, Mishin V, Cominelli F. A new strategy in design of +RNA virus infectious clones enabling their stable propagation in E. coli. Virology. 2001 Mar 15;281(2):272–280.
   PubMed Web of Science ®Google Scholar
• Schwartz O, Albert ML. Biology and pathogenesis of chikungunya virus. Nat Rev. 2010 Jul;8(7):491–500.
   Google Scholar
• Strauss JH, Strauss EG. The alphaviruses: gene expression, replication, and evolution. Microbiol Rev. 1994 Sep;58(3):491–562.
   PubMedGoogle Scholar
• Arankalle VA, Shrivastava S, Cherian S, et al. Genetic divergence of chikungunya viruses in India (1963-2006) with special reference to the 2005-2006 explosive epidemic. J Gen Virol. 2007 Jul;88(Pt 7):1967–1976.
   PubMed Web of Science ®Google Scholar
• Weaver SC, Reisen WK. Present and future arboviral threats. Antiviral Res. 2010 Feb;85(2):328–345.
   PubMed Web of Science ®Google Scholar
• Couderc T, Khandoudi N, Grandadam M, et al. Prophylaxis and therapy for chikungunya virus infection. J Infect Dis. 2009 Aug 15;200(4):516–523.
   PubMed Web of Science ®Google Scholar
• Queyriaux B, Simon F, Grandadam M, et al. Clinical burden of chikungunya virus infection. Lancet Infect Dis. 2008 Jan;8(1):2–3.
   PubMed Web of Science ®Google Scholar
• Burt FJ, Rolph MS, Rulli NE, et al. Chikungunya: a re-emerging virus. Lancet. 2012 Feb 18;379(9816):662–671.
   PubMed Web of Science ®Google Scholar
• Queyriaux B, Armengaud A, Jeannin C, et al. Chikungunya in Europe. Lancet. 2008 Mar 1;371(9614):723–724.
   PubMed Web of Science ®Google Scholar
• Enserink M. ENTOMOLOGY: A Mosquito Goes Global. Science (New York, NY). 2008 May 16;320(5878):864–866.
   Google Scholar
• Weaver SC, Osorio JE, Livengood JA, et al. Chikungunya virus and prospects for a vaccine. Expert Rev Vaccines. 2012 Sep;11(9):1087–1101.
   PubMed Web of Science ®Google Scholar
• Dhiman RC, Pahwa S, Dhillon GP, et al. Climate change and threat of vector-borne diseases in India: are we prepared? Parasitol Res. 2010 Mar;106(4):763–773.
   PubMed Web of Science ®Google Scholar
• Pistone T, Ezzedine K, Schuffenecker I, et al. An imported case of chikungunya fever from Madagascar: use of the sentinel traveller for detecting emerging arboviral infections in tropical and European countries. Travel Med Infect Dis. 2009 Jan;7(1):52–54.
   PubMed Web of Science ®Google Scholar
• Randolph SE, Rogers DJ. The arrival, establishment and spread of exotic diseases: patterns and predictions. Nat Rev Microbiol. 2010 May;8(5):361–371.
   PubMed Web of Science ®Google Scholar
• Weaver SC. Urbanization and geographic expansion of zoonotic arboviral diseases: mechanisms and potential strategies for prevention. Trends Microbiol. 2013 Aug;21(8):360–363.
   PubMed Web of Science ®Google Scholar
• Thiboutot MM, Kannan S, Kawalekar OU, et al. Chikungunya: a potentially emerging epidemic? PLoS Negl Trop Dis. 2010;4(4):e623.
   PubMed Web of Science ®Google Scholar
• Petersen LR, Stramer SL, Powers AM. Chikungunya virus: possible impact on transfusion medicine. Transfus Med Rev. 2010 Jan;24(1):15–21.
   PubMed Web of Science ®Google Scholar
• Schwameis M, Buchtele N, Wadowski PP, et al. Chikungunya vaccines in development. Hum Vaccin Immunother. 2015 Nov;10:0.
   Web of Science ®Google Scholar
• Gorchakov R, Wang E, Leal G, et al. Attenuation of chikungunya virus vaccine strain 181/clone 25 is determined by two amino acid substitutions in the E2 envelope glycoprotein. J Virol. 2012;86(11):6084–6096.
   PubMed Web of Science ®Google Scholar
• Plante KS, Rossi SL, Bergren NA, et al. Extended preclinical safety, efficacy and stability testing of a live-attenuated chikungunya vaccine candidate. PLoS Negl Trop Dis. 2015 Sep;9(9):e0004007.
   Web of Science ®Google Scholar
• Edelman R, Tacket CO, Wasserman SS, et al. Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Am J Trop Med Hyg. 2000 Jun;62(6):681–685.
   PubMed Web of Science ®Google Scholar
• Inovio. Inovio pharmaceuticals breakthrough DNA-based monoclonal antibody therapy completely protects animals from lethal viral challenge. 2014 [cited March 19, 2016]. Available from: http://ir.inovio.com/news/news-releases/news-releases-details/2014/Inovio-Pharmaceuticals-Breakthrough-DNA-Based-Monoclonal-Antibody-Therapy-Completely-Protects-Animals-From-Lethal-Viral-Challenge/.
   Google Scholar
• Hallengärd D, Kakoulidou M, Lulla A, et al. Novel attenuated chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice. J Virol. 2014;88(5):2858–2866.
   PubMed Web of Science ®Google Scholar
• Scherer WF, Cupp EW, Dziem GM, et al. Mesenteronal infection threshold of an epizootic strain of Venezuelan encephalitis virus in Culex (Melanoconion) taeniopus mosquitoes and its implication to the apparent disappearance of this virus strain from an enzootic habitat in Guatemala. Am J Trop Med Hyg. 1982 Sep;31(5):1030–1037.
   PubMed Web of Science ®Google Scholar
• Brault AC, Powers AM, Ortiz D, et al. Venezuelan equine encephalitis emergence: enhanced vector infection from a single amino acid substitution in the envelope glycoprotein. Proc Natl Acad Sci U S A. 2004 Aug 3;101(31):11344–11349.
   PubMed Web of Science ®Google Scholar
• Deardorff ER, Weaver SC. Vector competence of Culex (Melanoconion) taeniopus for equine-virulent subtype IE strains of Venezuelan equine encephalitis virus. Am J Trop Med Hyg. 2010 Jun;82(6):1047–1052.
   PubMed Web of Science ®Google Scholar
• Weaver SC, Ferro C, Barrera R, et al. Venezuelan equine encephalitis. Annu Rev Entomol. 2004;49:141–174.
   PubMed Web of Science ®Google Scholar
• Scherer WF, Weaver SC, Taylor CA, et al. Vector competence of Culex (Melanoconion) taeniopus for allopatric and epizootic Venezuelan equine encephalomyelitis viruses. Am J Trop Med Hyg. 1987 Jan;36(1):194–197.
   PubMed Web of Science ®Google Scholar
• Smart DL, Trainer DO. Serologic evidence of Venezuelan equine encephalitis in some wild and domestic populations of southern Texas. J Wildl Dis. 1975 Apr;11(2):195–200.
   PubMedGoogle Scholar
• Weaver SC, Pfeffer M, Marriott K, et al. Genetic evidence for the origins of Venezuelan equine encephalitis virus subtype IAB outbreaks. Am J Trop Med Hyg. 1999 Mar;60(3):441–448.
   PubMed Web of Science ®Google Scholar
• Kitchen LW, Vaughn DW. Role of U.S. military research programs in the development of U.S.-licensed vaccines for naturally occurring infectious diseases. Vaccine. 2007 Oct;25(41):7017–7030.
   PubMed Web of Science ®Google Scholar
• Lemon SM, Thaul S, Fisseha S, et al., editors. Protecting our forces: improving vaccine acquisition and availability in the U.S. military. Institute of Medicine (U.S.). Committee on a strategy for minimizing the impact of naturally occurring infectious diseases of military importance. 1st ed. Washington (DC): National Academies Press; 2002.
   Google Scholar
• Paessler S, Weaver SC. Vaccines for Venezuelan equine encephalitis. Vaccine. 2009 Nov 5;27 Suppl 4:D80–5.
   PubMed Web of Science ®Google Scholar
• Kinney RM, Chang GJ, Tsuchiya KR, et al. Attenuation of Venezuelan equine encephalitis virus strain TC-83 is encoded by the 5ʹ-noncoding region and the E2 envelope glycoprotein. J Virol. 1993 Mar;67(3):1269–1277.
   PubMed Web of Science ®Google Scholar
• Phillpotts RJ, Wright AJ. TC-83 vaccine protects against airborne or subcutaneous challenge with heterologous mouse-virulent strains of Venezuelan equine encephalitis virus. Vaccine. 1999 Feb 26;17(7–8):982–988.
   PubMed Web of Science ®Google Scholar
• Pittman PR, Makuch RS, Mangiafico JA, et al. Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine. 1996 Mar;14(4):337–343.
   PubMed Web of Science ®Google Scholar
• Kenney JL, Volk SM, Pandya J, et al. Stability of RNA virus attenuation approaches. Vaccine. 2011 Mar 9;29(12):2230–2234.
   PubMed Web of Science ®Google Scholar
• Zhang R, Hryc CF, Cong Y, et al. 4.4 A cryo-EM structure of an enveloped alphavirus Venezuelan equine encephalitis virus. Embo J. 2011 Sep 14;30(18):3854–3863.
   PubMed Web of Science ®Google Scholar
• Perri S, Greer CE, Thudium K, et al. An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J Virol. 2003 Oct;77(19):10394–10403.
   PubMed Web of Science ®Google Scholar
• Polo JM, Gardner JP, Ji Y, et al. Alphavirus DNA and particle replicons for vaccines and gene therapy. Dev Biol (Basel). 2000;104:181–185.
   PubMedGoogle Scholar
• Riabov V, Tretyakova I, Alexander RB, et al. Anti-tumor effect of the alphavirus-based virus-like particle vector expressing prostate-specific antigen in a HLA-DR transgenic mouse model of prostate cancer. Vaccine. 2015 Aug 26;33:5386–5395.
   PubMed Web of Science ®Google Scholar
• Nelson EL, Prieto D, Alexander TG, et al. Venezuelan equine encephalitis replicon immunization overcomes intrinsic tolerance and elicits effective anti-tumor immunity to the ‘self’ tumor-associated antigen, neu in a rat mammary tumor model. Breast Cancer Res Treat. 2003 Dec;82(3):169–183.
   PubMed Web of Science ®Google Scholar
• Pushko P, Tretyakova I. Alphavirus replicon vectors for prophylactic applications and cancer interventions. In: Lukashevich IS, Shirwan H, editors. Novel technologies for vaccine development. Vienna: Springer; 2014. p. 61–87. 2014 edition.
   Google Scholar
• Pushko P, Parker M, Ludwig GV, et al. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology. 1997 Dec 22;239(2):389–401.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Pushko P, Anderson K, et al. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis. 2002 May;8(5):503–507.
   PubMed Web of Science ®Google Scholar
• Pushko P, Geisbert J, Parker M, et al. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J Virol. 2001 Dec;75(23):11677–11685.
   PubMed Web of Science ®Google Scholar
• Pushko P, Bray M, Ludwig GV, et al. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine. 2000 Aug 15;19(1):142–153.
   PubMed Web of Science ®Google Scholar
• Berge TO, Banks IS, Tigertt WD. Attenuation of Venezuelan equine encephalomyelitis virus by in vitro cultivation in guinea-pig heart cells. Am J Trop Med Hyg. 1961;73:209–218.
   Google Scholar
• Grabenstein JD, Pittman PR, Greenwood JT, et al. Immunization to protect the US Armed Forces: heritage, current practice, and prospects. Epidemiol Rev. 2006;28:3–26.
   PubMed Web of Science ®Google Scholar
• Hoke CH Jr. History of U.S. military contributions to the study of viral encephalitis. Mil Med. 2005 Apr;170(4 Suppl):92–105.
   PubMedGoogle Scholar
• Cheng BY, Ortiz-Riano E, De La Torre JC, et al. Arenavirus genome rearrangement for the development of live attenuated vaccines. J Virol. 2015 Jul;89(14):7373–7384.
   PubMed Web of Science ®Google Scholar
• Lowen AC, Boyd A, Fazakerley JK, et al. Attenuation of bunyavirus replication by rearrangement of viral coding and noncoding sequences. J Virol. 2005 Jun;79(11):6940–6946.
   PubMed Web of Science ®Google Scholar
• Pushko P, Parker MD, Smith JF, et al. Inventor Live attenuated venezuelan equine encephalitis vaccine. US Patent 6296854 B1. 2001.
   Google Scholar
• Reisen WK. Ecology of West Nile virus in North America. Viruses. 2013 Sep;5(9):2079–2105.
   PubMed Web of Science ®Google Scholar
• Petersen LR, Brault AC, Nasci RS. West Nile virus: review of the literature. Jama. 2013 Jul 17;310(3):308–315.
   PubMed Web of Science ®Google Scholar
• Frost MJ, Zhang J, Edmonds JH, et al. Characterization of virulent West Nile virus Kunjin strain, Australia, 2011. Emerg Infect Dis. 2012 May;18(5):792–800.
   PubMed Web of Science ®Google Scholar
• Halstead SB, Thomas SJ. New Japanese encephalitis vaccines: alternatives to production in mouse brain. Expert Rev Vaccines. 2011 Mar;10(3):355–364.
   PubMed Web of Science ®Google Scholar
• Rice CM, Grakoui A, Galler R, et al. Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation. New Biol. 1989 Dec;1(3):285–296.
   PubMedGoogle Scholar
• Cohen J. Unfilled vials. Science. 2016 Jan 1;351(6268):16–19.
   PubMed Web of Science ®Google Scholar
• Lukashevich IS, Carrion R Jr., Salvato MS, et al. Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine. 2008 Sep 26;26(41):5246–5254.
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Hensley L, Asiedu C, et al. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med. 2011 Sep;17(9):1128–1131.
   PubMed Web of Science ®Google Scholar
• Safronetz D, Mire C, Rosenke K, et al. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses. PLoS Negl Trop Dis. 2015 Apr;9(4):e0003736.
   PubMed Web of Science ®Google Scholar
• Kang SM, Pushko P, Bright RA, et al. Influenza virus-like particles as pandemic vaccines. Curr Top Microbiol Immunol. 2009;333:269–289.
   PubMedGoogle Scholar
• Tretyakova I, Hidajat R, Hamilton G, et al. Preparation of quadri-subtype influenza virus-like particles using bovine immunodeficiency virus gag protein. Virology. 2016;487:163–171.
   PubMed Web of Science ®Google Scholar
• Akahata W, Yang ZY, Andersen H, et al. A virus-like particle vaccine for epidemic chikungunya virus protects nonhuman primates against infection. Nat Med. 2010 Mar;16(3):334–338.
   PubMed Web of Science ®Google Scholar
• Carrillo-Tripp M, Shepherd CM, Borelli IA, et al. VIPERdb2: an enhanced and web API enabled relational database for structural virology. Nucleic Acids Res. 2009 Jan;37(Databaseissue):D436–D442.
   PubMed Web of Science ®Google Scholar